Core Viewpoint - The article highlights recent developments from several companies under Sequoia Capital in the healthcare sector, focusing on innovative treatments and technologies that have received regulatory approvals or achieved significant milestones. Group 1: Weisheng Pharmaceutical - Weisheng Pharmaceutical announced that its core product, Lonapegsomatropin (维臻高), has been officially approved by the National Medical Products Administration of China for the treatment of growth hormone deficiency in children aged 3 and above [3][6]. - Lonapegsomatropin is the only long-acting growth hormone clinically proven to be superior to daily growth hormone injections, marking a significant milestone for Weisheng Pharmaceutical in its transition from research to commercialization [6]. Group 2: Xihu Biology - Xihu Biology has achieved important milestones in its red blood cell drug development, focusing on both tumor treatment and immune tolerance [8]. - The company published significant research results in top international journals, including the first engineered red blood cell-antibody conjugate drug (WTX-212) showing good safety and objective response in late-stage solid tumor patients [9]. Group 3: Jinshi Technology - Jinshi Technology participated in drafting the national standard for single-molecule gene sequencing, marking a new phase of standardization in this field [13][17]. - The standard aims to establish a unified framework for evaluating and comparing the performance of various single-molecule sequencing technologies, addressing long-standing issues of ambiguity in definitions and evaluation criteria [17]. Group 4: Huayi Lekang - Huayi Lekang announced that its gene therapy product for Hemophilia A, GS1191-0445, has completed enrollment for its key registration clinical study, entering the commercialization phase [19]. - This gene therapy aims to provide a revolutionary shift from lifelong repeated treatments to a single administration that offers long-term efficacy [21]. Group 5: Jingfeng Medical - Jingfeng Medical has successfully installed its multi-port surgical robot in two leading private medical institutions in Armenia, marking a significant step in its global expansion [22]. - The company is recognized as the first in China and the second globally to have multi-port, single-port, and bronchoscopic surgical robots approved for market, showcasing its innovative model of technology export and capability building [24]. Group 6: Sequoia Capital's Investment Strategy - Sequoia Capital has invested in over 250 healthcare companies with distinct technological characteristics and high growth potential, covering various sectors including innovative drugs, medical devices, and digital healthcare [25].